Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cigna (CI – Research Report) and Hologic (HOLX – Research Report).
Cigna (CI)
Morgan Stanley analyst Erin Wright maintained a Buy rating on Cigna on February 2 and set a price target of $365.00. The company’s shares closed last Friday at $323.84, close to its 52-week high of $328.37.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
Currently, the analyst consensus on Cigna is a Moderate Buy with an average price target of $374.45, which is a 18.6% upside from current levels. In a report issued on February 1, Deutsche Bank also upgraded the stock to Buy with a $370.00 price target.
See the top stocks recommended by analysts >>
Hologic (HOLX)
Morgan Stanley analyst Tejas Savant maintained a Hold rating on Hologic yesterday and set a price target of $84.00. The company’s shares closed last Friday at $72.44.
According to TipRanks.com, Savant ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hologic with a $81.60 average price target, representing a 9.7% upside. In a report issued on January 24, RBC Capital also maintained a Hold rating on the stock with a $76.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CI:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Cigna (NYSE:CI) Surges on Q4 Beat, Raises Dividend By 14%
- Early notable gainers among liquid option names on February 2nd
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
- Cigna sees FY24 adjusted EPS at least $28.25, consensus $28.29
